Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACIU AC Immune	$1.70 +3.7%	$1.99	$1.43 ▼ $4.98	$170.70M	1.49	324,608 shs	245,718 shs
KROS Keros Therapeutics	$14.26 +0.4%	$11.63	$9.12 ▼ $72.37	$578.41M	1.39	801,421 shs	840,384 shs
TRVI Trevi Therapeutics	$6.59 +1.9%	$5.75	$2.30 ▼ $7.39	$637.13M	0.41	1.12 million shs	1.49 million shs
VECT VectivBio	$16.85	$16.85	$4.25 ▼ $16.98	$573.24M	0.11	N/A	N/A

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACIU AC Immune	+3.66%	+14.86%	-14.14%	-35.61%	-27.66%
KROS Keros Therapeutics	+0.35%	-0.28%	+32.16%	+26.08%	-75.35%
TRVI Trevi Therapeutics	+1.85%	+9.47%	+1.38%	+66.84%	+137.05%
VECT VectivBio	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACIU AC Immune	2.3948 of 5 stars	3.5	2.0	0.0	0.0	2.5	0.8	1.3
KROS Keros Therapeutics	3.0978 of 5 stars	3.3	2.0	0.0	0.0	4.2	5.0	0.0
TRVI Trevi Therapeutics	3.5995 of 5 stars	4.7	2.0	0.0	0.0	3.0	4.2	0.0
VECT VectivBio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACIU AC Immune	3.00	Buy	$12.00	605.88% Upside
KROS Keros Therapeutics	2.57	Moderate Buy	$40.33	182.84% Upside
TRVI Trevi Therapeutics	3.30	Buy	$17.56	166.50% Upside
VECT VectivBio	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest ACIU, TRVI, KROS, and VECT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/9/2025	KROS Keros Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$43.00 ➝ $25.00
4/8/2025	TRVI Trevi Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$24.00 ➝ $24.00
4/3/2025	ACIU AC Immune	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
4/1/2025	KROS Keros Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$15.00 ➝ $15.00
4/1/2025	KROS Keros Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00 ➝ $40.00
3/19/2025	TRVI Trevi Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.00 ➝ $20.00
3/19/2025	TRVI Trevi Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.50 ➝ $12.50
3/19/2025	TRVI Trevi Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$21.00 ➝ $21.00
3/19/2025	TRVI Trevi Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$25.00 ➝ $24.00
3/14/2025	ACIU AC Immune	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
3/11/2025	TRVI Trevi Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$12.00 ➝ $20.00

(Data available from 4/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACIU AC Immune	$27.31M	6.25	N/A	N/A	$2.12 per share	0.80
KROS Keros Therapeutics	$3.55M	162.93	N/A	N/A	$11.09 per share	1.29
TRVI Trevi Therapeutics	N/A	N/A	N/A	N/A	$1.29 per share	N/A
VECT VectivBio	$27.34M	20.97	N/A	N/A	N/A	∞

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACIU AC Immune	-$60.41M	-$0.58	N/A	N/A	N/A	N/A	-28.26%	-18.98%	5/12/2025 (Estimated)
KROS Keros Therapeutics	-$152.99M	-$5.01	N/A	N/A	N/A	-27,890.94%	-41.74%	-38.42%	5/6/2025 (Estimated)
TRVI Trevi Therapeutics	-$29.07M	-$0.47	N/A	N/A	N/A	N/A	-63.31%	-57.06%	5/6/2025 (Estimated)
VECT VectivBio	-$93.74M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest ACIU, TRVI, KROS, and VECT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	KROS Keros Therapeutics	$0.1614	N/A	N/A	N/A	$62.01 million	N/A
5/12/2025	Q1 2025	ACIU AC Immune	-$0.22	N/A	N/A	N/A	$0.32 million	N/A
5/6/2025	Q1 2025	TRVI Trevi Therapeutics	-$0.13	N/A	N/A	N/A	N/A	N/A
3/18/2025	Q4 2024	TRVI Trevi Therapeutics	-$0.12	-$0.11	+$0.01	-$0.11	N/A	N/A
2/26/2025	Q4 2024	KROS Keros Therapeutics	-$1.36	-$1.14	+$0.22	-$1.14	$37.32 million	$3.04 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACIU AC Immune	N/A	N/A	N/A	N/A	N/A
KROS Keros Therapeutics	N/A	N/A	N/A	N/A	N/A
TRVI Trevi Therapeutics	N/A	N/A	N/A	N/A	N/A
VECT VectivBio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACIU AC Immune	N/A	1.86	1.86
KROS Keros Therapeutics	N/A	19.03	19.03
TRVI Trevi Therapeutics	N/A	7.38	7.38
VECT VectivBio	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACIU AC Immune	51.36%
KROS Keros Therapeutics	71.56%
TRVI Trevi Therapeutics	95.76%
VECT VectivBio	N/A

Insider Ownership

Company	Insider Ownership
ACIU AC Immune	4.60%
KROS Keros Therapeutics	22.90%
TRVI Trevi Therapeutics	24.37%
VECT VectivBio	9.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACIU AC Immune	140	100.41 million	94.39 million	Optionable
KROS Keros Therapeutics	100	40.56 million	31.23 million	Optionable
TRVI Trevi Therapeutics	20	96.68 million	58.13 million	Optionable
VECT VectivBio	30	34.02 million	N/A	No Data

ACIU, TRVI, KROS, and VECT Headlines

Recent News About These Companies

Ironwood’s shares sink as FDA demands new trial for lead drug

April 15, 2025 | msn.com

A brain biotech launches with Roche’s spare parts

February 13, 2025 | biopharmadive.com

Aravax Continues International Expansion with Appointment of Aled Williams as Chief Business Officer

January 21, 2025 | markets.businessinsider.com

CDR-Life Appoints Sarah Holland, PhD, as Chief Business Officer

December 5, 2024 | finance.yahoo.com

Recent advances in clinical practice: mastering the challenge—managing IBS symptoms in IBD

November 12, 2024 | gut.bmj.com

Graft versus Host Disease Market to Increase at a CAGR of 9.9% During the Study Period (2020–2034) | DelveInsight

September 23, 2024 | finance.yahoo.com

Etherio Group: 2024 CMI 25

September 21, 2024 | meetingsnet.com

Compare with VectivBio Holding AG (VECT)

May 29, 2024 | msn.com

enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors

May 15, 2024 | finance.yahoo.com

Vicore Pharma Holding: Vicore Expands and Strengthens its Board of Directors

May 14, 2024 | finanznachrichten.de

Vicore Expands and Strengthens its Board of Directors

May 14, 2024 | finance.yahoo.com

Short Bowel Syndrome Market by 2032: Forecast Report Estimates Significant Growth

April 5, 2024 | uk.finance.yahoo.com

FDA approves DMD treatment from Italfarmaco

March 31, 2024 | cen.acs.org

Pipeline moves: Approval prospects for SBS candidate rise after Phase III trial meets endpoints

March 18, 2024 | msn.com

Ironwood Nabs Phase III Win, Still Sees Stock Nosedive

March 1, 2024 | biospace.com

Ironwood felled by mixed data in short bowel syndrome trial

March 1, 2024 | pharmaphorum.com

UPDATE 3-Ironwood's bowel disease drug meets main goal of late-stage study

March 1, 2024 | msn.com

Ironwood's bowel disease treatment meets main goal in late-stage trial

February 29, 2024 | reuters.com

Why Is Gastrointestinal Healthcare Focused Ironwood Pharmaceuticals Stock Sinking On Thursday?

February 29, 2024 | benzinga.com

Only two sleeps left until February 31!

February 29, 2024 | ft.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACIU, TRVI, KROS, and VECT Company Descriptions

AC Immune NASDAQ:ACIU

$1.70 +0.06 (+3.66%)

Closing price 04/28/2025 04:00 PM Eastern

Extended Trading

$1.80 +0.10 (+5.82%)

As of 04/28/2025 04:51 PM Eastern

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

Keros Therapeutics NASDAQ:KROS

$14.26 +0.05 (+0.35%)

Closing price 04/28/2025 04:00 PM Eastern

Extended Trading

$14.20 -0.06 (-0.42%)

As of 04/28/2025 06:42 PM Eastern

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Trevi Therapeutics NASDAQ:TRVI

$6.59 +0.12 (+1.85%)

Closing price 04/28/2025 04:00 PM Eastern

Extended Trading

$6.52 -0.08 (-1.14%)

As of 04/28/2025 06:04 PM Eastern

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

VectivBio NASDAQ:VECT

$16.85 0.00 (0.00%)

As of 04/25/2025

VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). VectivBio Holding AG was incorporated in 2019 and is headquartered in Basel, Switzerland. As of June 29, 2023, VectivBio Holding AG operates as a subsidiary of Ironwood Pharmaceuticals, Inc.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time